# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older.Approval f...
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...
Submission based on the positive Phase 3 RESTORE studyMirum holds orphan designation for chenodiol in CTXPotential to have firs...
Stifel analyst Dae Gon Ha maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $48 to $66.
Citigroup analyst David Lebowitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $...
JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target fr...
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price targ...